HOME >> BIOLOGY >> NEWS
Defective movement of cell's power plants implicated in commom inherited neurological disorder

WASHINGTON, DC, January 16, 2007 Contrary to previous thinking, the inefficient movement of cell's "power plants" - the mitochondria - within a cell, rather than their low energy production, may be a contributing factor in the development of Charcot-Marie-Tooth disease (CMT), new research shows.

The study, published in the January 10 issue of The Journal of Neuroscience, is the first to show that mutations in the gene Mitofusin 2 (MFN2), known to cause a form of CMT, also disrupt the movement of the cell's mitochondria, which deliver energy within the cell. A minor disruption in mitochondria movement reduces the energy supply, weakening or even killing the cell.

In CMT, which affects 1 in 2,500 individuals, nerves and muscles in the feet and hands weaken, causing numbness and, in many cases, the loss of function. CMT affects peripheral nerves, among the longest nerves in the body where energy transport is vital.

"This work is of critical importance because the design of effective therapeutic approaches requires an understanding of the underlying disease mechanism," says Brian Popko, PhD, professor in neurological diseases at the University of Chicago who is not connected to the study.

The new research also provides strong evidence that effective energy transportation is key to long cell life, according to senior author Robert H. Baloh, PhD, at the Washington University School of Medicine.

Using rat tissue, Baloh and colleagues removed neurons similar to those affected in CMT patients. They then inserted mutant MFN2 genes in the nucleus of those cells using engineered viruses. Time-lapse videos were taken with a fluorescent microscope in order to observe the speed at which the mitochondria moved. In normal cells, mitochondria are highly mobile. However, in the neurons with mutant MFN2 genes, movement is significantly reduced.

Still unknown is exactly how the mutated MFN2 protein alters mitochondri
'"/>

Contact: Sara Harris
sharris@sfn.org
202-962-4000
Society for Neuroscience
16-Jan-2007


Page: 1 2

Related biology news :

1. Defective sweet taste receptor gene shapes cat cuisine
2. St. Jude study yields secrets of chromosome movement
3. Cellular message movement captured on video
4. Information processing in the central nervous system: the signalling system controlling movement
5. Eye movement tasks can be used to assess fetal alcohol spectrum disorders
6. Electric fish shed light on ways the brain directs movement
7. How movement lubricates bone joints
8. UNC scientists solve mystery of how largest cellular motor protein powers movement
9. 1st international study group for new movement discipline
10. Electronic chip, interacting with the brain, modifies pathways for controlling movement
11. Research links ecstasy to survival of key movement-related cells in brain

Post Your Comments:
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: